Issues and controversies surrounding the diagnosis and treatment of social anxiety disorder

被引:11
作者
Dalrymple, Kristy L. [1 ,2 ]
机构
[1] Brown Univ, Rhode Isl Hosp, Providence, RI 02905 USA
[2] Brown Univ, Alpert Med Sch, Providence, RI 02905 USA
关键词
cognitive behavior therapy; comorbidity; diagnosis; etiology; pharmacotherapy; social phobia; treatment; COGNITIVE-BEHAVIORAL THERAPY; QUALITY-OF-LIFE; AVOIDANT PERSONALITY-DISORDER; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; PUBLIC-SPEAKING FEARS; 1ST; DECADES; EXPOSURE THERAPY; GENERAL-POPULATION;
D O I
10.1586/ERN.12.81
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although much has been learned about social anxiety disorder (SAD) in recent decades, many questions and controversies surrounding its diagnosis and treatment have remained. Similar to the state of affairs with other psychiatric disorders, no clear pathophysiology has been identified for SAD, and the question of where to draw the line between shyness, SAD and even avoidant personality disorder continues to be debated. Much of the evidence to date suggests that among persons with SAD, it is under-recognized and undertreated; however, other researchers contend that it may be overdiagnosed in some individuals. Questions also remain as to how best treat these individuals, such as with pharmacotherapy, psychotherapy or a combination of the two. The aim of this review is to provide an overview of the controversies related to the diagnosis and treatment of SAD. In addition, suggestions for future research are provided that could perhaps clarify these remaining questions, such as maximizing treatment efficacy by targeting broader outcomes such as quality of life and addressing common comorbidities that occur with SAD.
引用
收藏
页码:993 / 1008
页数:16
相关论文
共 154 条
[91]  
McCrone Paul, 2009, Cognitive Behaviour Therapy, V38, P91, DOI 10.1080/16506070802561074
[92]   Comorbid generalized anxiety disorder in primary social phobia: Symptom severity, functional impairment, and treatment response [J].
Mennin, DS ;
Heimberg, RG ;
Jack, MS .
JOURNAL OF ANXIETY DISORDERS, 2000, 14 (04) :325-343
[93]   Vulnerability factors among children at risk for anxiety disorders [J].
Merikangas, KR ;
Avenevoli, S ;
Dierker, L ;
Grillon, C .
BIOLOGICAL PSYCHIATRY, 1999, 46 (11) :1523-1535
[94]   Psychiatrists' ascertained treatment needs for mental disorders in a population-based sample [J].
Messias, Erick ;
Eaton, William ;
Nestadt, Gerald ;
Bienvenu, O. Joseph ;
Samuels, Jack .
PSYCHIATRIC SERVICES, 2007, 58 (03) :373-377
[95]   National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry [J].
Mojtabai, Ramin ;
Olfson, Mark .
ARCHIVES OF GENERAL PSYCHIATRY, 2010, 67 (01) :26-36
[96]  
Mowrer OH, 1947, HARVARD EDUC REV, V17, P102
[97]   Behavioral and neural analysis of extinction [J].
Myers, KM ;
Davis, M .
NEURON, 2002, 36 (04) :567-584
[98]   Revised prevalence estimates of mental disorders in the United States - Using a clinical significance criterion to reconcile 2 surveys' estimates [J].
Narrow, WE ;
Rae, DS ;
Robins, LN ;
Regier, DA .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (02) :115-123
[99]   Stress-induced changes in human salivary alpha-amylase activity-associations with adrenergic activity [J].
Nater, UM ;
La Marca, R ;
Florin, L ;
Moses, A ;
Langhans, W ;
Koller, MM ;
Ehlert, U .
PSYCHONEUROENDOCRINOLOGY, 2006, 31 (01) :49-58
[100]  
National Institute of Drug Abuse, 2005, RES REP PRESCR DRUGS